FIRST LINE,
YOUR CHOICE

VPRIV is a first-line enzyme
replacement
therapy (ERT)
for type 1 Gaucher patients. ^1,2

VPRIV's safety and efficacy were studied in the largest clinical trial program of an ERT for type 1 Gaucher disease across three clinical trials (n=99; aged ≥ 4 years).^1,3

Treatment-naïve: patients who had not received disease-specific treatment within the 30 months prior to starting VPRIV.⁴

Treatment-experienced: patients previously treated with imiglucerase for a minimum of 30 consecutive months prior to switching to VPRIV.⁵

Treatment-naïve: patients who had not received disease-specific treatment within the 30 months prior to starting VPRIV.⁴

Treatment-experienced: patients previously treated with imiglucerase for a minimum of 30 consecutive months prior to switching to VPRIV.⁵

MAKE VPRIV YOUR FIRST CHOICE

VPRIV has been studied in pediatric (aged ≥ 4 years) and adult patients with type 1 Gaucher disease.¹

HOW DOES VPRIV WORK?

VPRIV is designed to replace the missing or deficient glucocerebrosidase enzyme in patients with type 1 Gaucher disease.¹

Learn More

Dosing & Administration

The recommended starting dose for treatment-naïve patients 4 years of age and older is 60 U/kg every other week as a 60-minute IV infusion.¹ VPRIV should be administered under the supervision of a healthcare professional.¹

Learn More

TAKEDA SUPPORT PROGRAMS

Takeda is a leader in rare disease, dedicated to providing product support for your patients every step of the way.

Learn More

STAY CONNECTED!

Fill in the required fields to stay up to date with news and announcements about VPRIV.

FIRST NAME*

LAST NAME*

EMAIL ADDRESS*

*By checking this box and clicking “Submit,” you certify that you are at least 18 years old, a US resident, and you are opting to receive information about VPRIV and other information from Takeda. You will be able to opt out of these communications using the unsubscribe feature.

Takeda respects your personal information. All personal and/or medical information you have provided will be kept confidential and will not be used or distributed to anyone for any purpose other than what is explained in our Privacy Notice Statement. We encourage you to read our Privacy Notice Statement. This consent will be in effect until such a time as you opt out of the program.

FIRST LINE, YOUR CHOICE

MAKE VPRIV YOUR FIRST CHOICE

FIRST LINE,
YOUR CHOICE